{"id":6848,"date":"2011-07-04T11:32:00","date_gmt":"2011-07-04T09:32:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=6848"},"modified":"2023-12-21T11:30:13","modified_gmt":"2023-12-21T10:30:13","slug":"leukocytapheresis-in-pediatric-patients-with-ulcerative-colitis-2","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/leukocytapheresis-in-pediatric-patients-with-ulcerative-colitis-2\/","title":{"rendered":"Leukocytapheresis in pediatric patients with ulcerative colitis"},"content":{"rendered":"
\n

Takeshi Tomomasa<\/a> 1<\/a><\/sup>, Hitoshi Tajiri<\/a>, Seiichi Kagimoto<\/a>, Toshiaki Shimizu<\/a>, Atsushi Yoden<\/a>, Kosuke Ushijima<\/a>, Keiichi Uchida<\/a>, Hiroaki Kaneko<\/a>, Daiki Abukawa<\/a>, Mutsuko Konno<\/a>, Shun-ichi Maisawa<\/a>, Takao Kohsaka<\/a>, Akio Kobayashi<\/a>, Japanese Study Group for Pediatric Ulcerative Colitis<\/a>. J Pediatr Gastroenterol Nutr. <\/a>2011 Jul;53(1):34-9. doi: 10.1097\/MPG.0b013e31821058bc.<\/p>\n<\/div>\n\n

\n

Objective:\u00a0<\/strong>Leukocytapheresis (LCAP) is a nonpharmacologic therapy that has recently been used to treat ulcerative colitis (UC). This multicenter open-label study prospectively assessed the efficacy and safety of LCAP in pediatric patients with UC. Patients and methods:\u00a0<\/strong>Twenty-three patients ages 8 to 16 years with moderate (n = 19) to severe (n = 4) steroid-resistant UC were enrolled. One of 2 LCAP columns with different volumes (model EX and the half-volume model EI) was selected, according to body weight. LCAP was performed once per week for 5 consecutive weeks. Clinical and laboratory data were collected at predetermined time points. The primary endpoint was decreased stool frequency\/hematochezia score, and secondary endpoints were clinical, laboratory, and endoscopic improvements. Results:\u00a0<\/strong>The stool frequency\/hematochezia score decreased significantly from 4.5 \u00b1 1.2 before treatment to 1.6 \u00b1 1.9 after the fifth treatment. Clinical parameters, including stool frequency, presence of visible blood, abdominal pain, and body temperature, were significantly improved. Fecal calprotectin decreased significantly. Endoscopic findings evaluated using Matts score also improved (P < 0.01). The steroid dose decreased from 1.1 \u00b1 0.4 mg\/kg before treatment to 0.8 \u00b1 0.5 mg\/kg after treatment. There were no significant differences in changes between the EX and EI columns. The incidence of adverse effects was 61%, although none was serious. The most common adverse effects were decreased hematocrit and hemoglobin concentration. Conclusions:\u00a0<\/strong>The present study showed that LCAP was well tolerated in children with UC, mostly moderate, and was as effective as in adults. The types of pediatric patients best suited to LCAP remain to be determined.<\/p>\n<\/div>\n\n

\n

https:\/\/pubmed.ncbi.nlm.nih.gov\/21694533\/<\/a><\/p>\n<\/div>\n\n

\n

Leukocytapheresis in Pediatric Patients With Ulcerative Coli… : Journal of Pediatric Gastroenterology and Nutrition (lww.com)<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Takeshi Tomomasa 1, Hitoshi Tajiri, Seiichi Kagimoto, Toshiaki Shimizu, Atsushi Yoden, Kosuke Ushijima, Keiichi Uchida, Hiroaki Kaneko, Daiki Abukawa, Mutsuko Konno, Shun-ichi Maisawa, Takao Kohsaka, Akio Kobayashi, Japanese Study Group for Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2011 Jul;53(1):34-9. doi: 10.1097\/MPG.0b013e31821058bc. Objective:\u00a0Leukocytapheresis (LCAP) is a nonpharmacologic therapy that has recently been used to treat ulcerative colitis (UC). This multicenter open-label study prospectively assessed the efficacy and safety of LCAP […]<\/p>\n","protected":false},"template":"","scientific_tags":[157,654,424,74,767,100,96,405,97,156,605,523,766,271,615,306],"class_list":["post-6848","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-efficacy","scientific_tags-fecal-calprotectin","scientific_tags-gma","scientific_tags-leukocytapheresis","scientific_tags-moderate","scientific_tags-multicenter","scientific_tags-open-label","scientific_tags-pediatric","scientific_tags-prospective","scientific_tags-safety","scientific_tags-steroid-refractory-2","scientific_tags-steroid-tapering","scientific_tags-stool-frequency","scientific_tags-study","scientific_tags-tolerability","scientific_tags-ulcerative-colitis"],"acf":[],"yoast_head":"\nLeukocytapheresis in pediatric patients with ulcerative colitis - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-in-pediatric-patients-with-ulcerative-colitis-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leukocytapheresis in pediatric patients with ulcerative colitis - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Takeshi Tomomasa 1, Hitoshi Tajiri, Seiichi Kagimoto, Toshiaki Shimizu, Atsushi Yoden, Kosuke Ushijima, Keiichi Uchida, Hiroaki Kaneko, Daiki Abukawa, Mutsuko Konno, Shun-ichi Maisawa, Takao Kohsaka, Akio Kobayashi, Japanese Study Group for Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2011 Jul;53(1):34-9. doi: 10.1097\/MPG.0b013e31821058bc. Objective:\u00a0Leukocytapheresis (LCAP) is a nonpharmacologic therapy that has recently been used to treat ulcerative colitis (UC). This multicenter open-label study prospectively assessed the efficacy and safety of LCAP […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-in-pediatric-patients-with-ulcerative-colitis-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-21T10:30:13+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-in-pediatric-patients-with-ulcerative-colitis-2\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-in-pediatric-patients-with-ulcerative-colitis-2\/\",\"name\":\"Leukocytapheresis in pediatric patients with ulcerative colitis - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2011-07-04T09:32:00+00:00\",\"dateModified\":\"2023-12-21T10:30:13+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-in-pediatric-patients-with-ulcerative-colitis-2\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Leukocytapheresis in pediatric patients with ulcerative colitis - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-in-pediatric-patients-with-ulcerative-colitis-2\/","og_locale":"fr_FR","og_type":"article","og_title":"Leukocytapheresis in pediatric patients with ulcerative colitis - Adacyte","og_description":"Takeshi Tomomasa 1, Hitoshi Tajiri, Seiichi Kagimoto, Toshiaki Shimizu, Atsushi Yoden, Kosuke Ushijima, Keiichi Uchida, Hiroaki Kaneko, Daiki Abukawa, Mutsuko Konno, Shun-ichi Maisawa, Takao Kohsaka, Akio Kobayashi, Japanese Study Group for Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2011 Jul;53(1):34-9. doi: 10.1097\/MPG.0b013e31821058bc. Objective:\u00a0Leukocytapheresis (LCAP) is a nonpharmacologic therapy that has recently been used to treat ulcerative colitis (UC). This multicenter open-label study prospectively assessed the efficacy and safety of LCAP […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-in-pediatric-patients-with-ulcerative-colitis-2\/","og_site_name":"Adacyte","article_modified_time":"2023-12-21T10:30:13+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-in-pediatric-patients-with-ulcerative-colitis-2\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-in-pediatric-patients-with-ulcerative-colitis-2\/","name":"Leukocytapheresis in pediatric patients with ulcerative colitis - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2011-07-04T09:32:00+00:00","dateModified":"2023-12-21T10:30:13+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-in-pediatric-patients-with-ulcerative-colitis-2\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/6848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=6848"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=6848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}